Posted by Leanne Kodsmann on
Human Complement from Innovative Research was used in the following study:
Lukmanee Tradtrantip, Tianjiao Duan, Michael R. Yeaman, Alan S. Verkman
Journal of Neuroinflammation
December 2019, 16:57
"... Neuromyelitis optica spectrum disorder (herein called NMO) is an inflammatory demyelinating disease that can be initiated by binding of immunoglobulin G autoantibodies (AQP4-IgG) to aquaporin-4 on astrocytes, causing complement-dependent cytotoxicity (CDC) and downstream inflammation. The increased NMO pathology in rodents deficient in complement regulator protein CD59 following passive transfer of AQP4-IgG has suggested the potential therapeutic utility of increasing the expression of complement regulator proteins...Human complement was purchased from Innovative Research (Novi, MI)..."
Related products available from Innovative Research also include: